280,345 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Acquired by Stonepine Capital Management LLC

Stonepine Capital Management LLC acquired a new stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN) in the 3rd quarter, HoldingsChannel reports. The firm acquired 280,345 shares of the company’s stock, valued at approximately $3,560,000. UroGen Pharma accounts for approximately 2.2% of Stonepine Capital Management LLC’s portfolio, making the stock its 14th largest holding.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. raised its holdings in shares of UroGen Pharma by 90.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock worth $103,000 after buying an additional 3,856 shares in the last quarter. BNP Paribas Financial Markets grew its position in UroGen Pharma by 221.8% in the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after acquiring an additional 5,890 shares during the last quarter. Intech Investment Management LLC acquired a new position in UroGen Pharma during the third quarter worth about $155,000. SG Americas Securities LLC bought a new position in shares of UroGen Pharma in the third quarter worth about $179,000. Finally, ProShare Advisors LLC acquired a new stake in shares of UroGen Pharma in the 2nd quarter valued at approximately $199,000. 91.29% of the stock is currently owned by institutional investors.

UroGen Pharma Trading Up 1.9 %

Shares of URGN stock traded up $0.24 during trading hours on Wednesday, hitting $12.72. 95,232 shares of the company’s stock traded hands, compared to its average volume of 497,939. The stock has a market cap of $298.28 million, a PE ratio of -3.96 and a beta of 1.12. The stock’s 50 day simple moving average is $12.38 and its 200 day simple moving average is $14.01. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. UroGen Pharma Ltd. has a 12 month low of $10.60 and a 12 month high of $20.70.

UroGen Pharma (NASDAQ:URGN) last announced its earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.29. The company had revenue of $25.20 million for the quarter, compared to the consensus estimate of $24.22 million. During the same period in the prior year, the business earned ($0.68) earnings per share. On average, sell-side analysts anticipate that UroGen Pharma Ltd. will post -3.1 EPS for the current year.

Wall Street Analysts Forecast Growth

URGN has been the subject of a number of research analyst reports. Oppenheimer reiterated an “outperform” rating and set a $40.00 price objective on shares of UroGen Pharma in a research report on Wednesday, October 16th. Guggenheim started coverage on shares of UroGen Pharma in a report on Thursday, August 22nd. They set a “buy” rating and a $40.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of UroGen Pharma in a report on Tuesday, October 15th. Finally, EF Hutton Acquisition Co. I raised UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $48.38.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.